Bradycardia News and Research

RSS

Bradycardia, ("heart slowness"), as applied to adult medicine, is defined as a resting heart rate of under 60 beats per minute, though it is seldom symptomatic until the rate drops below 50 beat/min.

Takeda announces accelerated approval from FDA for new lung cancer treatment

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that ALUNBRIG (brigatinib) has received Accelerated Approval from the U.S. Food and Drug Administration for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer who have progressed on or are intolerant to crizotinib.

28 Apr 2017

FDA approves first drug for treating rare form of Batten disease

The U.S. Food and Drug Administration today approved Brineura (cerliponase alfa) as a treatment for a specific form of Batten disease. Brineura is the first FDA-approved treatment to slow loss of walking ability in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase-1 (TPP1) deficiency.

27 Apr 2017

Pacing program can lead to seven-fold reduction in fainting episodes

Patients with recurrent fainting episodes (syncope) who received a pacemaker delivering a pacing program designed to detect and stop the abnormal heart rhythms that precede syncope had a seven-fold reduction in fainting compared with patients in a placebo pacing group, according to research presented at the American College of Cardiology's 66th Annual Scientific Session.

20 Mar 2017

Scientists create organ-on-a-chip that can mimic heart's biomechanical properties

The human heart beats more than 2.5 billion times in an average lifetime. Now scientists at Vanderbilt University have created a three-dimensional organ-on-a-chip that can mimic the heart's amazing biomechanical properties.

23 Feb 2017

Houston Methodist offers world's smallest heart device for patients with bradycardia

Houston Methodist Hospital is one of the first hospitals in Texas to offer the world's smallest pacemaker for patients with bradycardia, a condition characterized by a slow heart rate, usually fewer than 60 beats per minute.

2 Feb 2017

Epclusa drug receives FDA approval for treating adult patients with chronic HCV

The U.S. Food and Drug Administration approved Epclusa to treat adult patients with chronic hepatitis C virus (HCV) both with and without cirrhosis (advanced liver disease).

28 Jun 2016

Micra Transcatheter Pacing System approved to treat heart rhythm disorders

The U.S. Food and Drug Administration today approved the first pacemaker that does not require the use of wired leads to provide an electrical connection between the pulse-generating device and the heart. While the Micra Transcatheter Pacing System works like other pacemakers to regulate heart rate, the self-contained, inch-long device is implanted directly in the right ventricle chamber of the heart.

7 Apr 2016

Bradycardia does not increase cardiovascular disease risk

Bradycardia - a slower than normal heartbeat - does not increase the risk of developing cardiovascular disease, according to a study conducted by researchers at Wake Forest Baptist Medical Center. The study is published in the Jan.19 online edition of the Journal of American Medical Association Internal Medicine.

19 Jan 2016

Bridion injection approved to reverse effects of neuromuscular blocking drugs used during certain types of surgery

The U.S. Food and Drug Administration today approved Bridion (sugammadex) injection to reverse the effects of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide, which are used during certain types of surgery in adults.

16 Dec 2015

Egalet, Teva sign agreement to commercialize SPRIX Nasal Spray in Israel, Gaza and the West Bank

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced a collaboration agreement with Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company.

14 Dec 2015

Second-line bosutinib offers ‘durable’ response for chronic phase CML patients

Four-year results for an ongoing study of second-line bosutinib indicate that the tyrosine kinase inhibitor offers long-term efficacy with manageable side effects for patients with chronic phase chronic myeloid leukaemia.

27 Nov 2015

Mylan releases Clozapine Orally Disintegrating Tablets in U.S.

Mylan N.V. today announced the U.S. launch of Clozapine Orally Disintegrating Tablets, 25 mg and 100 mg, the generic version of Jazz Pharmaceutical's FazaClo.

24 Nov 2015

Vibration-based technology reduces apneic events, improves critical clinical parameters in premature infants

Scientists and clinicians at the University of Massachusetts Medical School, Wyss Institute for Biologically Inspired Engineering, and the Beth Israel Deaconess Medical Center have shown in a clinical trial that a new, vibration-based prevention technology tested in a neonatal intensive care unit (NICU) reduces apneic events and improves critical clinical parameters in prematurely born infants.

24 Nov 2015

Vibration-based therapy can successfully treat apnea events in preterm infants

Researchers from Beth Israel Deaconess Medical Center's Neonatal Intensive Care Unit (NICU), the Wyss Institute for Biologically Inspired Engineering at Harvard University and the University of Massachusetts Medical School have found that a vibration-based therapy known as stochastic resonance (SR) stimulation can successfully treat preterm infants experiencing apnea of prematurity (AOP), disrupted breathing, bradycardia (slowed heart rate) and oxygen desaturation (diminished oxygen levels).

23 Nov 2015

Allergan settles patent litigation with Amneal related to NAMENDA XR extended release capsules

Allergan plc, today announced that its subsidiaries Forest Laboratories, LLC and Forest Laboratories Holdings, Ltd., along with Adamas Pharmaceuticals, Inc., have entered into a settlement agreement with Amneal Pharmaceuticals LLC and related companies and subsidiaries.

10 Sep 2015

Egalet announces launch of OXAYDO (oxycodone HCI, USP) Tablets and IMPACT-Rx initiative

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on discovering, developing and commercializing innovative pain treatments, today announced the launch of OXAYDO (oxycodone HCI, USP) tablets -CII in the United States.

9 Sep 2015

Egalet to present scientific data on SPRIX Nasal Spray at Painweek 2015

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on discovering, developing, and commercializing innovative pain treatments, today announced that researchers will be presenting scientific data on SPRIX (ketorolac tromethamine) Nasal Spray, Egalet-001, an abuse-deterrent, extended-release, oral morphine product candidate, and Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product in development, at PainWeek 2015 to be held September 8 to 12 in Las Vegas, Nevada.

1 Sep 2015

Research: Patients test drive pacemaker outside the skin before deciding on permanent implant

Patients are test driving a pacemaker outside the skin before deciding whether to have a permanent implant, reveals novel research presented today at EHRA EUROPACE - CARDIOSTIM 2015 by Professor Michael Giudici, director of arrhythmia services in the Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, US.

22 Jun 2015

Cardiac device wearers ought to keep safe distance from smartphones to prevent unwanted painful shocks

Cardiac device wearers should keep a safe distance from smartphones to avoid unwanted painful shocks or pauses in function, reveals research presented today at EHRA EUROPACE -- CARDIOSTIM 2015 by Dr. Carsten Lennerz, first author and cardiology resident in the Clinic for Heart and Circulatory Diseases, German Heart Centre, Munich, Germany.